Previous close | 0.2050 |
Open | 0.2050 |
Bid | 0.2100 x 3603200 |
Ask | 0.2150 x 12700 |
Day's range | 0.2050 - 0.2150 |
52-week range | 0.1150 - 0.3550 |
Volume | |
Avg. volume | 806,329 |
Market cap | 49.191M |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0800 |
Earnings date | 23 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 21 July 2020 |
1y target est | 0.68 |
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Key Insights Nova Eye Medical's Annual General Meeting to take place on 22nd of November Total pay for CEO Tom Spurling...
FREMONT, Calif., April 12, 2023--Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that it has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its new canaloplasty device, iTrack™ Advance.